Results 121 to 130 of about 499,895 (395)

Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry [PDF]

, 2017
Background The long‐term efficacy and safety of alcohol septal ablation ( ASA ) in patients with highly symptomatic hypertrophic obstructive cardiomyopathy has been demonstrated. The aim
Adlova, Radka, Almaas, Vibeke Marie, Bartel, Thomas, Bundgaard, Henning, Cooper, Robert, Dabrowski, Maciej, Faber, Lothar, Hansen, Peter Riis, Horstkotte, Dieter, Januska, Jaroslav, Jensen, Morten Kvistholm, Krejci, Jan, Liebregts, Max, Seggewiss, Hubert, Stables, Rodney Hilton, ten Berg, Jurrien, Veselka, Josef   +16 more
core   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Patients with obstructive hypertrophic cardiomyopathy have increased symptomatic burden. Mavacamten was recently approved for treatment of obstructive hypertrophic cardiomyopathy based on 2 randomized controlled trials.
Diego Ramonfaur, Alessio Gasperetti, Victoria E. Blake, Bryana Rivers, Ali A. Kassamali, Edward K. Kasper, Lili A. Barouch, Katherine C. Wu, Jose A. Madrazo, Richard T. Carrick   +9 more
doaj   +1 more source

Cardiac pacing in hypertrophic cardiomyopathy: a cohort with 24 years of follow-up [PDF]

, 2008
FUNDAMENTO: O benefício da estimulação cardíaca em pacientes portadores de cardiomiopatia hipertrófica (CMH) tem sido questionado, sendo escassas as pesquisas sobre este assunto no Brasil.
COSTA, Roberto, FERNÁNDEZ, Edmundo Arteaga, IANNI, Barbara Maria, MADY, Charles, MARTINELLI FILHO, Martino, SILVA, Lenine Angelo Alves, SIQUEIRA, Sérgio   +6 more
core   +3 more sources

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.

Journal of the American College of Cardiology, 2023
M. Maron, Ahmad Masri, L. Choudhury, I. Olivotto, S. Saberi, Andrew Wang, P. García-Pavía, N. Lakdawala, Sherif F. Nagueh, F. Rader, A. Tower-Rader, A. Turer, C. Coats, M. Fifer, A. Owens, S. Solomon, H. Watkins, R. Barriales-Villa, C. Kramer, T. Wong, S. Paige, S. Heitner, S. Kupfer, F. Malik, L. Meng, A. Wohltman, T. Abraham   +26 more
semanticscholar   +1 more source

Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience.

Annals of Cardiothoracic Surgery, 2017
BACKGROUND Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by left ventricular hypertrophy in the absence of other etiologies. Clinical presentation may vary from asymptomatic to sudden cardiac death.
K. D. Kotkar, Sameh M. Said, J. Dearani, H. Schaff   +3 more
semanticscholar   +1 more source

Hypertrophic Obstructive Cardiomyopathy Masked by Tako-Tsubo Syndrome: A Case Report

Case Reports in Cardiology, 2012
Introduction. Left ventricular outflow obstruction might be part of the pathophysiological mechanism of Tako-tsubo cardiomyopathy. This obstruction can be masked by Tako-tsubo cardiomyopathy and diagnosed only by followup. Case Presentation.
Y. Daralammori, M. El Garhy, M. R. Gayed, A. Farah, B. Lauer, M. A. Secknus   +5 more
doaj   +1 more source

Significance of myocardial tenascin-C expression in left ventricular remodelling and long-term outcome in patients with dilated cardiomyopathy [PDF]

, 2015
Aim Dilated cardiomyopathy (DCM) has a variety of causes, and no useful approach to predict left ventricular (LV) remodelling and long-term outcome has yet been established.
Anzai, T, Ikeda, Y, Ishibashi-Ueda, H, Matsuyama, T-A, Nagai, T, Nakatani, T, Nakayama, T, Ogawa, H, Ohta-Ogo, K, Sugano, Y, Takeishi, Y, Yasuda, S, Yokokawa, T   +12 more
core   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

HYPERTROPHIC CARDIOMYOPATHY AS A PART OF INHERITED MALFORMATION SYNDROMES IN INFANTS

Вопросы современной педиатрии, 2011
The data of clinical and instrumental examination of two infantile patients with obstructive hypertrophic cardiomyopathy in association with marked multisystem involvement as a picture of inherited malformation syndromes are given.Key words: infants ...
M.V. Tural'chuk, G.A. Novik, A.Ya. Gudkova   +2 more
doaj